BACKGROUND: Several cancer therapies can prolong cardiac repolarization. This study assessed the potential of eribulin to affect cardiac repolarization in patients with advanced solid tumors. METHODS: In this Phase I, open-label, single-arm study, patients received eribulin mesylate (1.4 mg/m(2); Days 1 and 8 of a 21-day cycle). The primary objective was to assess the effect of eribulin on the QTcF pre- and post-infusion; QTcF and QTcNi were compared for ability to remove heart-rate dependence of the QT interval. Relationship between concentration of eribulin and ΔQTc was explored using linear mixed-effects analysis. Secondary objectives explored pharmacokinetics, safety, and tolerability. RESULTS: Twenty-six patients were enrolled. QTcNi was more effective than QTcF in correcting for heart-rate dependency of the QT interval. On Day 1, mean ΔQTcNi were ~0 at all timepoints. An apparent time-dependent increase in ΔQTc was observed: on Day 8, changes from baseline were larger and more variable, without clear relation to plasma levels of eribulin. Day 8 predose ΔQTcNi was 5 ms, post-infusion mean values ranged from 2 to 9 ms (largest mean ΔQTcNi at 6 h). No new or unexpected toxicities were reported. CONCLUSION: Eribulin demonstrated an acceptable safety profile and a minor prolongation of QTc not expected to be of clinical concern in oncology patients.
BACKGROUND: Several cancer therapies can prolong cardiac repolarization. This study assessed the potential of eribulin to affect cardiac repolarization in patients with advanced solid tumors. METHODS: In this Phase I, open-label, single-arm study, patients received eribulin mesylate (1.4 mg/m(2); Days 1 and 8 of a 21-day cycle). The primary objective was to assess the effect of eribulin on the QTcF pre- and post-infusion; QTcF and QTcNi were compared for ability to remove heart-rate dependence of the QT interval. Relationship between concentration of eribulin and ΔQTc was explored using linear mixed-effects analysis. Secondary objectives explored pharmacokinetics, safety, and tolerability. RESULTS: Twenty-six patients were enrolled. QTcNi was more effective than QTcF in correcting for heart-rate dependency of the QT interval. On Day 1, mean ΔQTcNi were ~0 at all timepoints. An apparent time-dependent increase in ΔQTc was observed: on Day 8, changes from baseline were larger and more variable, without clear relation to plasma levels of eribulin. Day 8 predose ΔQTcNi was 5 ms, post-infusion mean values ranged from 2 to 9 ms (largest mean ΔQTcNi at 6 h). No new or unexpected toxicities were reported. CONCLUSION: Eribulin demonstrated an acceptable safety profile and a minor prolongation of QTc not expected to be of clinical concern in oncology patients.
Authors: Elias Pean; Sigrid Klaar; Eva Gil Berglund; Tomas Salmonson; Jeanett Borregaard; Kenneth F Hofland; Jens Ersbøll; Eric Abadie; Rosa Giuliani; Francesco Pignatti Journal: Clin Cancer Res Date: 2012-07-24 Impact factor: 12.531
Authors: Javier Cortes; Joyce O'Shaughnessy; David Loesch; Joanne L Blum; Linda T Vahdat; Katarina Petrakova; Philippe Chollet; Alexey Manikas; Veronique Diéras; Thierry Delozier; Vladimir Vladimirov; Fatima Cardoso; Han Koh; Philippe Bougnoux; Corina E Dutcus; Seth Seegobin; Denis Mir; Nicole Meneses; Jantien Wanders; Chris Twelves Journal: Lancet Date: 2011-03-02 Impact factor: 79.321
Authors: L A Devriese; M Mergui-Roelvink; J Wanders; A Jenner; G Edwards; L Reyderman; W Copalu; F Peng; S Marchetti; J H Beijnen; J H M Schellens Journal: Invest New Drugs Date: 2012-05-05 Impact factor: 3.850
Authors: K Kitagawa; K Kawada; S Morita; M Inada; A Mitsuma; M Sawaki; S Iino; Y Inden; T Murohara; T Imai; Y Ando Journal: Ann Oncol Date: 2011-06-20 Impact factor: 32.976
Authors: Mary Ann Jordan; Kathryn Kamath; Tapas Manna; Tatiana Okouneva; Herbert P Miller; Celia Davis; Bruce A Littlefield; Leslie Wilson Journal: Mol Cancer Ther Date: 2005-07 Impact factor: 6.261
Authors: Antoinette R Tan; Eric H Rubin; Diana C Walton; Dale E Shuster; Y Nancy Wong; Fang Fang; Simon Ashworth; Lee S Rosen Journal: Clin Cancer Res Date: 2009-06-09 Impact factor: 12.531
Authors: Tatiana Okouneva; Olga Azarenko; Leslie Wilson; Bruce A Littlefield; Mary Ann Jordan Journal: Mol Cancer Ther Date: 2008-07 Impact factor: 6.261
Authors: J G Coen van Hasselt; Anubha Gupta; Ziad Hussein; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema Journal: Br J Clin Pharmacol Date: 2013-09 Impact factor: 4.335
Authors: Eric S Schafer; Rachel E Rau; Stacey Berg; Xiaowei Liu; Charles G Minard; David D'Adamo; Rachael Scott; Larisa Reyderman; Gresel Martinez; Sandhya Devarajan; Joel M Reid; Elizabeth Fox; Brenda J Weigel; Susan M Blaney Journal: Pediatr Blood Cancer Date: 2018-05-02 Impact factor: 3.167